Skip to main content

Bio-Rad Revenues Rise as Company Reaches $1 Billion Mark

NEW YORK, Feb. 13 (GenomeWeb News) - Bio-Rad Laboratories of Hercules, Calif. reported a 9.5 percent increase in revenue in the fourth quarter of 2003 as it reached the $1 billion mark for full-year sales.


Bio-Rad reported $266.2 million in fourth-quarter revenue, up from $243 million in the year-ago period. Revenues for the Life Sciences segment in the quarter were $130.2 million, up 6.6 percent year-over-year. Net income rose by 12.2 percent from $67.9 million, or $2.70 per share, in Q4 2002; to $76.2 million, or $3.00 per share, in Q4 2003.


R&D expenses for the fourth quarter rose as well, from $22.9 million in 2002 to $26.4 million in 2003.


As of Dec. 31, 2002, Bio-Rad had cash and cash equivalents of $148.6 million.


The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.